Personalis, Inc. (NASDAQ:PSNL) Stock Position Cut by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. cut its holdings in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 7.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 675,974 shares of the company's stock after selling 57,339 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.77% of Personalis worth $2,373,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Lightspeed Management Company L.L.C. purchased a new position in shares of Personalis in the 4th quarter worth about $47,169,000. Blue Water Life Science Advisors LP raised its holdings in Personalis by 13.3% in the fourth quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company's stock valued at $6,548,000 after buying an additional 132,900 shares during the period. Dimensional Fund Advisors LP raised its holdings in Personalis by 144.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock valued at $2,372,000 after buying an additional 242,141 shares during the period. Jane Street Group LLC raised its holdings in Personalis by 144.3% in the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company's stock valued at $2,320,000 after buying an additional 237,033 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of Personalis by 86.1% in the 4th quarter. Two Sigma Investments LP now owns 145,662 shares of the company's stock valued at $842,000 after acquiring an additional 67,403 shares during the period. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the company. Craig Hallum assumed coverage on Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, May 7th. Guggenheim assumed coverage on shares of Personalis in a research note on Thursday, May 15th. They set a "buy" rating and a $6.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price target on shares of Personalis in a research note on Thursday, April 10th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $7.67.

Personalis Price Performance

Shares of NASDAQ:PSNL traded down $0.60 during midday trading on Monday, reaching $6.86. The company had a trading volume of 1,153,487 shares, compared to its average volume of 1,143,571. Personalis, Inc. has a one year low of $1.41 and a one year high of $7.79. The stock has a market capitalization of $605.43 million, a P/E ratio of -5.31 and a beta of 1.95. The stock's fifty day moving average price is $5.36 and its 200-day moving average price is $4.84.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 48.78% and a negative net margin of 98.10%. As a group, sell-side analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.